More Articles

Access to medicines in Shaanxi province China Generics/Research | Posted 31/01/2014

Although generics in the Shaanxi province of China are significantly cheaper than their brand-name equivalents there is still room for improvement, according to a study of the prices and availabili...

Subsequent entry biologics approved in Canada Biosimilars/General | Posted 31/01/2014

Last update: 7 October 2016 In Canada, the regulatory body for the approval of biologicals is the Biologics and Genetic Therapies Directorate (BGTD) of the Health Products and Food Branch (HPF...

Giving EU Member States more freedom could increase early access to new drugs Reports | Posted 31/01/2014

A UK report urges giving European Union (EU) Member States greater freedoms to determine their own policies with respect to data protection and early access to medical innovations [1].

Generics game changer for Ireland Generics/General | Posted 31/01/2014

A new pharmacy in Dublin, Ireland, is offering customers savings of up to 80% on the price of drugs by focussing on generics. The news comes in light of legislation passed by both houses of Ireland...

Aurobindo to acquire seven generics businesses from Actavis Pharma News | Posted 31/01/2014

US generics maker Actavis and Indian generics maker Aurobindo Pharma (Aurobindo) announced on 17 January 2014 the signing of an offer for Aurobindo to acquire generics commercial operations in seve...

FDA to review insulin biosimilar Biosimilars/News | Posted 31/01/2014

Eli Lilly and Boehringer Ingelheim announced on 20 December 2013 that the US Food and Drug Administration (FDA) had accepted their New Drug Application (NDA) for a biosimilar insulin product.

Biosimilars developments during 2013 Biosimilars/General | Posted 24/01/2014

Last update: 12 February 2014 The past year has been a busy one for the biosimilars’ industry. One of the most important milestones during 2013 was the European approval of the first monoclona...

Trastuzumab ‘similar biologic’ to be launched in India Biosimilars/News | Posted 24/01/2014

India-based Biocon announced on 18 January 2013 that it was introducing its trastuzumab ‘similar biologic’ CANMAb to the Indian market.